Homepage Featured News
November 18, 2021
Data Presented at ACG Shows Guardant Health’s Blood-Based Test Accurately Detects Early-Stage Colorectal Cancer
This study indicates Guardant Health’s blood test could provide meaningful clinical performance in an average risk screening population
Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers
1,000-patient prospective study in 11 solid tumors will monitor ctDNA levels up to five years
July 20, 2021
Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorectal Cancer Screening During Pandemic
Selected Recipients of the New “Back to Screening Award for Research Advocacy Excellence” will be Honored at Fight Colorectal Cancer’s “Path to a Cure” Event in December 2021
November 18, 2021
Guardant Health Reports Third Quarter 2021 Financial Results
Achieved record revenue of $94.8 million, Growth of 35% and 58% year over year in clinical and biopharma volumes, respectively